Selpercatinib Extends PFS in First-line RET-Positive NSCLC
A randomized trial found that selpercatinib improved PFS by more than two-fold, but overall survival data remain immature.
Source: medscape.com
Page 35 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
ASCO Recommends Trilaciclib in Extensive-Stage Small Cell Lung Cancer in Guideline Update
In their updated guidelines for patients with small cell lung cancer (SCLC), ASCO has recommended the CDK4/6 inhibitor trilaciclib as a myeloid supportive agent for patients with untreated or previously treated extensive-stage SCLC who are receiving chemotherapy or chemoimmunotherapy.
Source: onclive.com
Current Standard Treatments for mNSCLC
Experts discuss the current standard treatment options for patients diagnosed with metastatic NSCLC (mNSCLC).
Source: ajmc.com
Metastatic NSCLC (mNSCLC) Biomarkers and Prognostic Factors Compared to Early-Stage NSCLC
Specialists review specific prognostic factors and biomarkers that help guide treatment selection for patients with metastatic NSCLC (mNSCLC) and discuss if these biomarkers differ from those observed in early-stage NSCLC.
Source: ajmc.com
From a Patient's Perspective: A Letter to Oncology Teams
Dear every oncology team...
Source: curetoday.com